PHST Pharsight Corp (MM)

Dr. Robert Leary Will Discuss Computational Methods for Model Evaluation; Dr. Mike Dunlavey Will Present Simplified Programming Approaches of Population Model User Interfaces MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver two poster presentations at the Population Approach Group in Europe (PAGE) 17th Annual Meeting in Marseille, France from June 18-20, 2008. Robert Leary, Ph.D., fellow, Pharsight Research and Development Group, will present work on computational methods for model evaluation. Mike Dunlavey, Ph.D., fellow, Pharsight Research and Development Group, will present new approaches on simplified programming of population model user interfaces. These poster sessions will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight's two presentations are: -- June 18: Simplified Programming of Population Model User Interfaces. Dr. Dunlavey will present a differential execution algorithm that allows a "painting" paradigm (called Dynamic Dialogs) as an alternative to event-based programming. This programming paradigm simplifies implementation of software products with complex graphical displays and user interface requirements. -- June 19: Nonparametric Analogs to POSTHOC Estimates for Exploratory Data Analysis. Dr. Leary will present a nonparametric model evaluation method to complement commonly used approaches for exploratory data analysis of possible covariate relationships. This work builds on applied research presented by industry colleagues at past PAGE conferences and on Dr. Leary's earlier work in the area of nonlinear mixed effects (NLME) analysis. "The development of advanced computational tools and next generation programming languages are integral to the continued growth of model-based drug development," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers' specific needs. Pharsight looks forward to presenting on specific elements of our vision for the future of model-based drug development, and is proud to again have such a wide presence at PAGE this year." Additional information about PAGE can be found at http://www.page-meeting.org/. About Pharsight Corporation Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/. Registered Trademarks and Trademarks Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations. DATASOURCE: Pharsight Corporation CONTACT: Investors, Douglas Sherk or Matthew Selinger, +1-415-896-6820, or Media, Steve DiMattia or Donald Takaya, +1-646-201-5445, all of EVC Group, for Pharsight Corporation Web site: http://www.pharsight.com/ http://www.page-meeting.org/

Copyright